Technical Analysis for STML - Stemline Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
STML closed unchanged on Friday, August 17, 2018, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|Weak or Absent||Down||Down||Up|
|See historical STML trend table...|
|Date||Alert Name||Type||% Chg|
|Aug 17||NR7||Range Contraction||0.00%|
|Aug 15||Earnings Movers||Other||-0.33%|
|Aug 14||200 DMA Resistance||Bearish||-1.62%|
|Aug 14||Shooting Star Candlestick||Bearish||-1.62%|
|Aug 14||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-1.62%|
|Aug 14||Earnings Movers||Other||-1.62%|
|Aug 13||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.00%|
|Aug 13||Outside Day||Range Expansion||0.00%|
|Aug 10||Shooting Star Candlestick||Bearish||1.34%|
|Aug 10||MACD Bullish Signal Line Cross||Bullish||1.34%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more STML news...
|52 Week High||20.55|
|52 Week Low||7.65|
|200-Day Moving Average||16.0963|
|50-Day Moving Average||16.2435|
|20-Day Moving Average||15.1775|
|10-Day Moving Average||14.91|
|Average True Range||0.714|
|Chandelier Exit (Long, 3 ATRs )||14.958|
|Chandelier Exit (Short, 3 ATRs )||16.047|
|Upper Bollinger Band||16.5404|
|Lower Bollinger Band||13.8146|
|Percent B (%b)||0.49|
|MACD Signal Line||-0.4824|
|Market Cap||355.34 Million|
|Num Shares||23.5 Million|
|Price-to-Earnings (P/E) Ratio||-6.13|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||15.75|
|Resistance 3 (R3)||15.72||15.48||15.65|
|Resistance 2 (R2)||15.48||15.33||15.50||15.62|
|Resistance 1 (R1)||15.32||15.24||15.40||15.35||15.58|
|Support 1 (S1)||14.92||14.93||15.00||14.95||14.72|
|Support 2 (S2)||14.68||14.84||14.70||14.68|
|Support 3 (S3)||14.52||14.68||14.65|
|Support 4 (S4)||14.55|